1
|
Wiesman AI, da Silva Castanheira J, Degroot C, Fon EA, Baillet S, Network QP. Adverse and compensatory neurophysiological slowing in Parkinson's disease. Prog Neurobiol 2023; 231:102538. [PMID: 37832713 PMCID: PMC10872886 DOI: 10.1016/j.pneurobio.2023.102538] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 09/27/2023] [Accepted: 10/09/2023] [Indexed: 10/15/2023]
Abstract
Patients with Parkinson's disease (PD) exhibit multifaceted changes in neurophysiological brain activity, hypothesized to represent a global cortical slowing effect. Using task-free magnetoencephalography and extensive clinical assessments, we found that neurophysiological slowing in PD is differentially associated with motor and non-motor symptoms along a sagittal gradient over the cortical anatomy. In superior parietal regions, neurophysiological slowing reflects an adverse effect and scales with cognitive and motor impairments, while across the inferior frontal cortex, neurophysiological slowing is compatible with a compensatory role. This adverse-to-compensatory gradient is sensitive to individual clinical profiles, such as drug regimens and laterality of symptoms; it is also aligned with the topography of neurotransmitter and transporter systems relevant to PD. We conclude that neurophysiological slowing in patients with PD signals both deleterious and protective mechanisms of the disease, from posterior to anterior regions across the cortex, respectively, with functional and clinical relevance to motor and cognitive symptoms.
Collapse
Affiliation(s)
- Alex I Wiesman
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada.
| | | | - Clotilde Degroot
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Edward A Fon
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Sylvain Baillet
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada.
| | - Quebec Parkinson Network
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| |
Collapse
|
2
|
Wiesman AI, Donhauser PW, Degroot C, Diab S, Kousaie S, Fon EA, Klein D, Baillet S. Aberrant neurophysiological signaling associated with speech impairments in Parkinson's disease. NPJ Parkinsons Dis 2023; 9:61. [PMID: 37059749 PMCID: PMC10104849 DOI: 10.1038/s41531-023-00495-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 03/16/2023] [Indexed: 04/16/2023] Open
Abstract
Difficulty producing intelligible speech is a debilitating symptom of Parkinson's disease (PD). Yet, both the robust evaluation of speech impairments and the identification of the affected brain systems are challenging. Using task-free magnetoencephalography, we examine the spectral and spatial definitions of the functional neuropathology underlying reduced speech quality in patients with PD using a new approach to characterize speech impairments and a novel brain-imaging marker. We found that the interactive scoring of speech impairments in PD (N = 59) is reliable across non-expert raters, and better related to the hallmark motor and cognitive impairments of PD than automatically-extracted acoustical features. By relating these speech impairment ratings to neurophysiological deviations from healthy adults (N = 65), we show that articulation impairments in patients with PD are associated with aberrant activity in the left inferior frontal cortex, and that functional connectivity of this region with somatomotor cortices mediates the influence of cognitive decline on speech deficits.
Collapse
Affiliation(s)
- Alex I Wiesman
- Montreal Neurological Institute, McGill University, 3801 Rue University, Montreal, QC, Canada
| | - Peter W Donhauser
- Montreal Neurological Institute, McGill University, 3801 Rue University, Montreal, QC, Canada
- Ernst Strüngmann Institute for Neuroscience, Frankfurt, Germany
| | - Clotilde Degroot
- Montreal Neurological Institute, McGill University, 3801 Rue University, Montreal, QC, Canada
| | - Sabrina Diab
- Department of Psychology, Université du Québec à Montréal, Montréal, QC, Canada
| | - Shanna Kousaie
- School of Psychology, University of Ottawa, Ottawa, ON, Canada
| | - Edward A Fon
- Montreal Neurological Institute, McGill University, 3801 Rue University, Montreal, QC, Canada
| | - Denise Klein
- Montreal Neurological Institute, McGill University, 3801 Rue University, Montreal, QC, Canada.
- Center for Research on Brain, Language and Music, McGill University, Montreal, QC, Canada.
| | - Sylvain Baillet
- Montreal Neurological Institute, McGill University, 3801 Rue University, Montreal, QC, Canada.
| |
Collapse
|
3
|
Das S, Abou-Haidar R, Rabalais H, Sun SDLW, Rosli Z, Chatpar K, Boivin MN, Tabatabaei M, Rogers C, Legault M, Lo D, Degroot C, Dagher A, Dyke SOM, Durcan TM, Seyller A, Doyon J, Poupon V, Fon EA, Genge A, Rouleau GA, Karamchandani J, Evans AC. The C-BIG Repository: an Institution-Level Open Science Platform. Neuroinformatics 2022; 20:139-153. [PMID: 34003431 PMCID: PMC9537233 DOI: 10.1007/s12021-021-09516-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/16/2021] [Indexed: 01/07/2023]
Abstract
In January 2016, the Montreal Neurological Institute-Hospital (The Neuro) declared itself an Open Science organization. This vision extends beyond efforts by individual scientists seeking to release individual datasets, software tools, or building platforms that provide for the free dissemination of such information. It involves multiple stakeholders and an infrastructure that considers governance, ethics, computational resourcing, physical design, workflows, training, education, and intra-institutional reporting structures. The C-BIG repository was built in response as The Neuro's institutional biospecimen and clinical data repository, and collects biospecimens as well as clinical, imaging, and genetic data from patients with neurological disease and healthy controls. It is aimed at helping scientific investigators, in both academia and industry, advance our understanding of neurological diseases and accelerate the development of treatments. As many neurological diseases are quite rare, they present several challenges to researchers due to their small patient populations. Overcoming these challenges required the aggregation of datasets from various projects and locations. The C-BIG repository achieves this goal and stands as a scalable working model for institutions to collect, track, curate, archive, and disseminate multimodal data from patients. In November 2020, a Registered Access layer was made available to the wider research community at https://cbigr-open.loris.ca , and in May 2021 fully open data will be released to complement the Registered Access data. This article outlines many of the aspects of The Neuro's transition to Open Science by describing the data to be released, C-BIG's full capabilities, and the design aspects that were implemented for effective data sharing.
Collapse
Affiliation(s)
- Samir Das
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.416102.00000 0004 0646 3639McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Rida Abou-Haidar
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Henri Rabalais
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Sonia Denise Lai Wing Sun
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.14709.3b0000 0004 1936 8649Clinical Research Unit, McGill University, Montreal, Quebec, Canada
| | - Zaliqa Rosli
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Krishna Chatpar
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Marie-Noëlle Boivin
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Mahdieh Tabatabaei
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Christine Rogers
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Melanie Legault
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Derek Lo
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Clotilde Degroot
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Alain Dagher
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.416102.00000 0004 0646 3639McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Stephanie O. M. Dyke
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.14709.3b0000 0004 1936 8649Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Thomas M. Durcan
- grid.14709.3b0000 0004 1936 8649Clinical Research Unit, McGill University, Montreal, Quebec, Canada ,grid.416102.00000 0004 0646 3639Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Annabel Seyller
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Julien Doyon
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.416102.00000 0004 0646 3639McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Viviane Poupon
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Edward A. Fon
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.14709.3b0000 0004 1936 8649Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Angela Genge
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.14709.3b0000 0004 1936 8649Clinical Research Unit, McGill University, Montreal, Quebec, Canada
| | - Guy A. Rouleau
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| | - Jason Karamchandani
- grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.14709.3b0000 0004 1936 8649Clinical Research Unit, McGill University, Montreal, Quebec, Canada
| | - Alan C. Evans
- grid.14709.3b0000 0004 1936 8649McGill Centre for Integrative Neuroscience, McGill University, Montréal, Québec, Canada ,grid.416102.00000 0004 0646 3639Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada ,grid.416102.00000 0004 0646 3639McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
| |
Collapse
|
4
|
de Rus Jacquet A, Bogard S, Normandeau CP, Degroot C, Postuma RB, Dupré N, Miyasaki JM, Monchi O, Martino D, Fon EA, Cicchetti F. Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism Relat Disord 2021; 91:66-76. [PMID: 34536727 PMCID: PMC8407944 DOI: 10.1016/j.parkreldis.2021.08.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 07/28/2021] [Accepted: 08/28/2021] [Indexed: 12/13/2022]
Abstract
Background The COVID-19 pandemic has necessitated the social isolation of the population and the rapid implementation of remote care for patients with neurodegenerative diseases. The objective of this study was to explore the perceived impact of confinement in patients with Parkinson's disease and document the effects of gender and living environment. Methods We recruited two cohorts from the Canadian provinces of Québec and Alberta, which differed in the dynamics of COVID-19 spreading at the time of the study, and administered a questionnaire on the perceived effects of confinement on daily living and disease management. Results The data reveals that approximately half of the patients experienced a change in one or more clinical symptoms, with differences observed between gender (e.g. day-to-day changes in slowness in men, aggravated headaches in women) and geographic location (e.g. increased depression in Alberta but reduced sleep quality in Québec). Furthermore, participants identifying as women or living in Alberta implemented more frequently home or online exercise. Lastly, high levels of satisfaction with phone or video consultations did not translate into a sustained interest to pursue this mode of healthcare. Conclusions This study suggests that COVID-19-related confinement affected Parkinson's disease manifestation and management. Patients also reported varying levels of interest to continue remote care. A number of differences reported in our study were seemingly related to gender and living environment.
Collapse
Affiliation(s)
- Aurelie de Rus Jacquet
- Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC, Canada; Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC, Canada.
| | - Sarah Bogard
- Neurodegenerative Diseases Group, Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Catherine P Normandeau
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, AB, Canada
| | - Clotilde Degroot
- Neurodegenerative Diseases Group, Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Ronald B Postuma
- Neurodegenerative Diseases Group, Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Nicolas Dupré
- Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC, Canada; Département de Médecine, Faculté de Médicine, Université Laval, Québec, QC, Canada
| | | | - Oury Monchi
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, AB, Canada
| | - Davide Martino
- Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, AB, Canada
| | - Edward A Fon
- Neurodegenerative Diseases Group, Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Francesca Cicchetti
- Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, QC, Canada; Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC, Canada.
| |
Collapse
|
5
|
Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, Dagher A, Das S, Desautels A, Drouin-Ouellet J, Durcan T, Gagnon JF, Genge A, Karamchandani J, Lafontaine AL, Sun SLW, Langlois M, Levesque M, Melmed C, Panisset M, Parent M, Poline JB, Postuma RB, Pourcher E, Rouleau GA, Sharp M, Monchi O, Dupré N, Fon EA. The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. J Parkinsons Dis 2021; 10:301-313. [PMID: 31868683 PMCID: PMC7029361 DOI: 10.3233/jpd-191775] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Genetic, biologic and clinical data suggest that Parkinson's disease (PD) is an umbrella for multiple disorders with clinical and pathological overlap, yet with different underlying mechanisms. To better understand these and to move towards neuroprotective treatment, we have established the Quebec Parkinson Network (QPN), an open-access patient registry, and data and bio-samples repository. OBJECTIVE To present the QPN and to perform preliminary analysis of the QPN data. METHODS A total of 1,070 consecutively recruited PD patients were included in the analysis. Demographic and clinical data were analyzed, including comparisons between males and females, PD patients with and without RBD, and stratified analyses comparing early and late-onset PD and different age groups. RESULTS QPN patients exhibit a male:female ratio of 1.8:1, an average age-at-onset of 58.6 years, an age-at-diagnosis of 60.4 years, and average disease duration of 8.9 years. REM-sleep behavior disorder (RBD) was more common among men, and RBD was associated with other motor and non-motor symptoms including dyskinesia, fluctuations, postural hypotension and hallucinations. Older patients had significantly higher rates of constipation and cognitive impairment, and longer disease duration was associated with higher rates of dyskinesia, fluctuations, freezing of gait, falls, hallucinations and cognitive impairment. Since QPN's creation, over 60 studies and 30 publications have included patients and data from the QPN. CONCLUSIONS The QPN cohort displays typical PD demographics and clinical features. These data are open-access upon application (http://rpq-qpn.ca/en/), and will soon include genetic, imaging and bio-samples. We encourage clinicians and researchers to perform studies using these resources.
Collapse
Affiliation(s)
- Ziv Gan-Or
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada.,Department of Human Genetics, McGill University, Montréal, QC, Canada
| | - Trisha Rao
- Clinical Research Unit, Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Etienne Leveille
- Montreal Neurological Institute, McGill University, Montréal, QC, Canada.,Faculty of Medicine, McGill University, Montréal, QC, Canada
| | - Clotilde Degroot
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Sylvain Chouinard
- Unité des trouves du mouvement André Barbeau, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Francesca Cicchetti
- Centre de Recherche du CHU de Québec, Axe Neurosciences, Québec, QC, Canada.,Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC, Canada
| | - Alain Dagher
- Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Samir Das
- McGill Centre for Integrative Neuroscience, Montreal Neurological Institute, Montreal, QC, Canada
| | - Alex Desautels
- Centre d'Études Avancées en Médecine du Sommeil and Neurology Service, H-pital du Sacré-C-eur de Montréal, Montréal, QC, Canada.,Department of Neurosciences, Université de Montréal, Montréal, QC, Canada
| | | | - Thomas Durcan
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Jean-François Gagnon
- Centre d'Études Avancées en Médecine du Sommeil and Neurology Service, H-pital du Sacré-C-eur de Montréal, Montréal, QC, Canada.,Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada
| | - Angela Genge
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada.,Clinical Research Unit, Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Jason Karamchandani
- Department of Pathology, Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Anne-Louise Lafontaine
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada.,Department of Neurology, McGill University Medical Centre, Montréal, QC, Canada
| | - Sonia Lai Wing Sun
- Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Mélanie Langlois
- Division of Neurosciences, CHU de Québec, Université Laval, Québec City, QC, Canada.,Department of Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada
| | - Martin Levesque
- Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC, Canada.,CERVO Brain Research Centre, Québec City, QC, Canada
| | - Calvin Melmed
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Jewish General Hospital, McGill University, Montréal, QC, Canada
| | - Michel Panisset
- Unité des trouves du mouvement André Barbeau, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Martin Parent
- Département de Psychiatrie & Neurosciences, Université Laval, Québec, QC, Canada.,CERVO Brain Research Centre, Québec City, QC, Canada
| | | | - Ronald B Postuma
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Emmanuelle Pourcher
- Division of Neurosciences, CHU de Québec, Université Laval, Québec City, QC, Canada.,Department of Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada
| | - Guy A Rouleau
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada.,Department of Human Genetics, McGill University, Montréal, QC, Canada
| | - Madeleine Sharp
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| | - Oury Monchi
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Departments of Clinical Neurosciences and Radiology, University of Calgary, AB, Canada.,Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, AB, Canada
| | - Nicolas Dupré
- Division of Neurosciences, CHU de Québec, Université Laval, Québec City, QC, Canada.,Department of Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada
| | - Edward A Fon
- Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.,Montreal Neurological Institute, McGill University, Montréal, QC, Canada
| |
Collapse
|
6
|
Trung J, Hanganu A, Jobert S, Degroot C, Mejia-Constain B, Kibreab M, Bruneau MA, Lafontaine AL, Strafella A, Monchi O. Transcranial magnetic stimulation improves cognition over time in Parkinson's disease. Parkinsonism Relat Disord 2019; 66:3-8. [PMID: 31300260 DOI: 10.1016/j.parkreldis.2019.07.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 04/19/2019] [Accepted: 07/06/2019] [Indexed: 12/13/2022]
Abstract
INTRODUCTION Cognitive impairment can occur in the early phase of Parkinson's disease and increases the risk of developing dementia. Cognitive deficits were shown to be associated with functional alterations in the dorsolateral prefrontal cortex (DLPFC) and caudate nucleus. Two previous transcranial magnetic stimulation studies over the left DLPFC showed short-term improvement in cognitive performance and focused on specific task. METHODS 28 patients with idiopathic Parkinson's disease and mild cognitive impairment received intermittent "theta burst" stimulation (iTBS) (active, N = 14; or sham, N = 14) over the left DLPFC, twice a day for three days with 1-2 days in between. Detailed neuropsychological assessment of five cognitive domains was performed before iTBS and on days 1, 10, and 30 after the last iTBS session. Composite Z-scores were calculated for each domain and for overall cognition. RESULTS Our results showed an increase in overall cognition up to one month in both groups but this effect was only significant in the active group. Improvements were seen in the attention domain for both groups and in the visuospatial domain in the active group only. No significant differences were found between the groups. CONCLUSION These preliminary findings suggest that active iTBS might improve overall cognitive performance in patients with Parkinson's disease with mild cognitive impairment and that this effect can last up to one month. This cognitive improvement, is likely mediated by improvement on visuospatial abilities. Further studies are needed to explore the potential of iTBS as a therapeutical tool to slow cognitive decline in patients with Parkinson's disease.
Collapse
Affiliation(s)
- Jessica Trung
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada
| | - Alexandru Hanganu
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada; Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, AB, Canada; Department of Psychology, University of Montreal, Montreal, QC, Canada
| | - Stevan Jobert
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada
| | - Clotilde Degroot
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada; McGill University, Montreal, QC, Canada
| | - Beatriz Mejia-Constain
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada
| | - Mekale Kibreab
- Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, AB, Canada
| | - Marie-Andrée Bruneau
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada
| | | | - Antonio Strafella
- Department of Medicine, Division of Neurology, University of Toronto, ON, Canada
| | - Oury Monchi
- CIUSSS Centre-Sud-de-l'Île-de-Montréal, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada; Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, AB, Canada; McGill University, Montreal, QC, Canada.
| |
Collapse
|
7
|
Nagano-Saito A, Bellec P, Hanganu A, Jobert S, Mejia-Constain B, Degroot C, Lafontaine AL, Lissemore JI, Smart K, Benkelfat C, Monchi O. Why Is Aging a Risk Factor for Cognitive Impairment in Parkinson's Disease?-A Resting State fMRI Study. Front Neurol 2019; 10:267. [PMID: 30967835 PMCID: PMC6438889 DOI: 10.3389/fneur.2019.00267] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Accepted: 02/27/2019] [Indexed: 01/12/2023] Open
Abstract
Using resting-state functional MRI (rsfMRI) data of younger and older healthy volunteers and patients with Parkinson's disease (PD) with and without mild cognitive impairment (MCI) and applying two different analytic approaches, we investigated the effects of age, pathology, and cognition on brain connectivity. When comparing rsfMRI connectivity strength of PD patients and older healthy volunteers, reduction between multiple brain regions in PD patients with MCI (PD-MCI) compared with PD patients without MCI (PD-non-MCI) was observed. This group difference was not affected by the number and location of clusters but was reduced when age was included as a covariate. Next, we applied a graph-theory method with a cost-threshold approach to the rsfMRI data from patients with PD with and without MCI as well as groups of younger and older healthy volunteers. We observed decreased hub function (measured by degree and betweenness centrality) mainly in the medial prefrontal cortex (mPFC) in older healthy volunteers compared with younger healthy volunteers. We also found increased hub function in the posterior medial structure (precuneus and the cingulate cortex) in PD-non-MCI patients compared with older healthy volunteers and PD-MCI patients. Hub function in these posterior medial structures was positively correlated with cognitive function in all PD patients. Together these data suggest that overlapping patterns of hub modifications could mediate the effect of age as a risk factor for cognitive decline in PD, including age-related reduction of hub function in the mPFC, and recruitment availability of the posterior medial structure, possibly to compensate for impaired basal ganglia function.
Collapse
Affiliation(s)
- Atsuko Nagano-Saito
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada.,Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada
| | - Pierre Bellec
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada.,Université de Montréal, Montreal, QC, Canada
| | - Alexandru Hanganu
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada.,Université de Montréal, Montreal, QC, Canada.,Cumming School of Medicine, Hotchkiss Brain Institute, Calgary, AB, Canada.,Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada
| | - Stevan Jobert
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada
| | - Béatriz Mejia-Constain
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada
| | - Clotilde Degroot
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada.,Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada
| | - Anne-Louise Lafontaine
- Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada.,Movement Disorders Unit, McGill University Health Center, Montreal, QC, Canada.,Department of Neurology, Montreal Neurological Hospital, Montreal, QC, Canada.,Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
| | - Jennifer I Lissemore
- Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada
| | - Kelly Smart
- Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada
| | - Chawki Benkelfat
- Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada
| | - Oury Monchi
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada.,Department of Neurology & Neurosurgery, and Psychiatry, McGill University, Montreal, QC, Canada.,Université de Montréal, Montreal, QC, Canada.,Cumming School of Medicine, Hotchkiss Brain Institute, Calgary, AB, Canada.,Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada.,Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
| |
Collapse
|
8
|
Hanganu A, Houde JC, Fonov VS, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, Chouinard S, Collins LD, Descoteaux M, Monchi O. White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease. Mov Disord 2018; 33:1139-1150. [PMID: 29683523 DOI: 10.1002/mds.27364] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Revised: 01/22/2018] [Accepted: 01/24/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In Parkinson's disease cognitive impairment is an early nonmotor feature, but it is still unclear why some patients are able to maintain their cognitive performance at normal levels, as quantified by neuropsychological tests, whereas others cannot. The objectives of this study were to perform a cross-sectional study and analyze the white matter changes in the cognitive and motor bundles in patients with Parkinson's disease. METHODS Sixteen Parkinson's disease patients with normal cognitive performance, 19 with mild cognitive impairment (based on their performance of 1.5 standard deviations below the healthy population mean), and 16 healthy controls were compared with respect to their tractography patterns between the cortical cognitive / motor regions and subcortical structures, using high angular resolution diffusion imaging and constrained spherical deconvolution computation. RESULTS Motor bundles showed decreased apparent fiber density in both PD groups, associated with a significant increase in diffusivity metrics, number of reconstructed streamlines, and track volumes, compared with healthy controls. By contrast, in the cognitive bundles, decreased fiber density in both Parkinson's groups was compounded by the absence of changes in diffusivity in patients with normal cognition, whereas patients with cognitive impairment had increased diffusivity metrics, lower numbers of reconstructed streamlines, and lower track volumes. CONCLUSIONS Both PD groups showed similar patterns of white matter neurodegeneration in the motor bundles, whereas cognitive bundles showed a distinct pattern: Parkinson's patients with normal cognition had white matter diffusivity metrics similar to healthy controls, whereas in patients with cognitive impairment white matter showed a neurodegeneration pattern. © 2018 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Alexandru Hanganu
- Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, Alberta, Canada.,Cumming School of Medicine, Hotchkiss Brain Institute, Calgary, Alberta, Canada
| | - Jean-Christophe Houde
- Sherbrooke Connectivity Imaging Lab (SCIL), Computer Science Department, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Vladimir S Fonov
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada
| | - Clotilde Degroot
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada
| | - Beatriz Mejia-Constain
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada
| | - Anne-Louise Lafontaine
- Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada.,Movement Disorders Unit, McGill University Health Center, Montréal, Quebec, Canada
| | - Valérie Soland
- Unité des Troubles du Mouvement André Barbeau, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
| | - Sylvain Chouinard
- Unité des Troubles du Mouvement André Barbeau, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
| | - Louis D Collins
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada
| | - Maxime Descoteaux
- Sherbrooke Connectivity Imaging Lab (SCIL), Computer Science Department, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Oury Monchi
- Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, Alberta, Canada.,Cumming School of Medicine, Hotchkiss Brain Institute, Calgary, Alberta, Canada.,Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.,Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada.,Department of Radiology, Faculty of Medicine, University of Montréal, Montréal, Quebec, Canada
| |
Collapse
|
9
|
Das S, Glatard T, Rogers C, Saigle J, Paiva S, MacIntyre L, Safi-Harab M, Rousseau ME, Stirling J, Khalili-Mahani N, MacFarlane D, Kostopoulos P, Rioux P, Madjar C, Lecours-Boucher X, Vanamala S, Adalat R, Mohaddes Z, Fonov VS, Milot S, Leppert I, Degroot C, Durcan TM, Campbell T, Moreau J, Dagher A, Collins DL, Karamchandani J, Bar-Or A, Fon EA, Hoge R, Baillet S, Rouleau G, Evans AC. Cyberinfrastructure for Open Science at the Montreal Neurological Institute. Front Neuroinform 2017; 10:53. [PMID: 28111547 PMCID: PMC5216036 DOI: 10.3389/fninf.2016.00053] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 12/01/2016] [Indexed: 12/20/2022] Open
Abstract
Data sharing is becoming more of a requirement as technologies mature and as global research and communications diversify. As a result, researchers are looking for practical solutions, not only to enhance scientific collaborations, but also to acquire larger amounts of data, and to access specialized datasets. In many cases, the realities of data acquisition present a significant burden, therefore gaining access to public datasets allows for more robust analyses and broadly enriched data exploration. To answer this demand, the Montreal Neurological Institute has announced its commitment to Open Science, harnessing the power of making both clinical and research data available to the world (Owens, 2016a,b). As such, the LORIS and CBRAIN (Das et al., 2016) platforms have been tasked with the technical challenges specific to the institutional-level implementation of open data sharing, including: Comprehensive linking of multimodal data (phenotypic, clinical, neuroimaging, biobanking, and genomics, etc.)Secure database encryption, specifically designed for institutional and multi-project data sharing, ensuring subject confidentiality (using multi-tiered identifiers).Querying capabilities with multiple levels of single study and institutional permissions, allowing public data sharing for all consented and de-identified subject data.Configurable pipelines and flags to facilitate acquisition and analysis, as well as access to High Performance Computing clusters for rapid data processing and sharing of software tools.Robust Workflows and Quality Control mechanisms ensuring transparency and consistency in best practices.Long term storage (and web access) of data, reducing loss of institutional data assets.Enhanced web-based visualization of imaging, genomic, and phenotypic data, allowing for real-time viewing and manipulation of data from anywhere in the world.Numerous modules for data filtering, summary statistics, and personalized and configurable dashboards. Implementing the vision of Open Science at the Montreal Neurological Institute will be a concerted undertaking that seeks to facilitate data sharing for the global research community. Our goal is to utilize the years of experience in multi-site collaborative research infrastructure to implement the technical requirements to achieve this level of public data sharing in a practical yet robust manner, in support of accelerating scientific discovery.
Collapse
Affiliation(s)
- Samir Das
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Tristan Glatard
- Department of Computer Science and Software Engineering, Concordia UniversityMontreal, QC, Canada
| | - Christine Rogers
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - John Saigle
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Santiago Paiva
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - Leigh MacIntyre
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Mouna Safi-Harab
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Marc-Etienne Rousseau
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Jordan Stirling
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Najmeh Khalili-Mahani
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
- Department of Computer Science and Software Engineering, Concordia UniversityMontreal, QC, Canada
| | - David MacFarlane
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Penelope Kostopoulos
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Pierre Rioux
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Cecile Madjar
- Douglas Mental Health University HospitalMontreal, QC, Canada
| | - Xavier Lecours-Boucher
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | | | - Reza Adalat
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Zia Mohaddes
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Vladimir S. Fonov
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - Sylvain Milot
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - Ilana Leppert
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | | | | | - Tara Campbell
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Jeremy Moreau
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - Alain Dagher
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - D. Louis Collins
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | | | - Amit Bar-Or
- Montreal Neurological InstituteMontreal, QC, Canada
| | | | - Rick Hoge
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - Sylvain Baillet
- Montreal Neurological InstituteMontreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological InstituteMontreal, QC, Canada
| | - Guy Rouleau
- Montreal Neurological InstituteMontreal, QC, Canada
| | - Alan C. Evans
- McGill Centre for Integrative Neuroscience, Montreal Neurological InstituteMontreal, QC, Canada
- Montreal Neurological InstituteMontreal, QC, Canada
| |
Collapse
|
10
|
Hanganu A, Bruneau MA, Degroot C, Bedetti C, Mejia-Constain B, Lafontaine AL, Chouinard S, Monchi O. Depressive symptoms in Parkinson's disease correlate with cortical atrophy over time. Brain Cogn 2016; 111:127-133. [PMID: 27918935 DOI: 10.1016/j.bandc.2016.11.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2016] [Revised: 10/25/2016] [Accepted: 11/07/2016] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Depressive symptoms are very common in patients with Parkinson's disease (PD) and have a significant impact on the quality of life. METHODS The present study analyzed the correlations between over-time changes in depressive symptoms and gray matter parameters of cortical thickness and subcortical volumes in non-demented PD patients. RESULTS A significant correlation was observed, between increased scores for depression over time and lower cortical thickness over time in the right temporo-parietal junction, right occipital medial region, right dorsolateral prefrontal cortex, right posterior cingulate region, left middle temporal as well as left supplementary motor area. Furthermore, the presence of depressive symptoms at baseline predicted increased cortical thinning over time in the left middle temporal, left anterior cingulate, right posterior cingulate and right parahippocampal cortices. Finally, a statistically significant negative correlation has been revealed between the thalamus' volume changes over time and the change in depressive symptoms scores. All other analyzed subcortical structures didn't reveal any significant correlations. CONCLUSION These results suggest that depressive symptoms in PD patients are associated with gray matter cortical thinning and thalamus volume shrinkage over time and higher scores of depressive symptoms at baseline correlate with a higher rate of cortical thinning longitudinally. The present study highlights the importance of addressing depressive symptoms in PD patients early in the disease.
Collapse
Affiliation(s)
- Alexandru Hanganu
- Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Calgary, AB, Canada; Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada.
| | - Marie-Andrée Bruneau
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada.
| | - Clotilde Degroot
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada; Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
| | - Christophe Bedetti
- Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré Cœur de Montréal, Montréal, QC, Canada.
| | - Béatriz Mejia-Constain
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada.
| | - Anne-Louise Lafontaine
- Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; Movement Disorders Unit, McGill University Health Centre, Montréal, QC, Canada.
| | - Sylvain Chouinard
- Unité des troubles du mouvement André Barbeau, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
| | - Oury Monchi
- Department of Clinical Neurosciences and Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, Calgary, AB, Canada; Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada; Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
| |
Collapse
|
11
|
Nagano-Saito A, Al-Azzawi MS, Hanganu A, Degroot C, Mejia-Constain B, Bedetti C, Lafontaine AL, Soland V, Chouinard S, Monchi O. Patterns of Longitudinal Neural Activity Linked to Different Cognitive Profiles in Parkinson's Disease. Front Aging Neurosci 2016; 8:275. [PMID: 27932974 PMCID: PMC5120116 DOI: 10.3389/fnagi.2016.00275] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 11/04/2016] [Indexed: 01/08/2023] Open
Abstract
Mild cognitive impairment in Parkinson's disease (PD) has been linked with functional brain changes. Previously, using functional magnetic resonance imaging (fMRI), we reported reduced cortico-striatal activity in patients with PD who also had mild cognitive impairment (MCI) vs. those who did not (non-MCI). We followed up these patients to investigate the longitudinal effect on the neural activity. Twenty-four non-demented patients with Parkinson's disease (non-MCI: 12, MCI: 12) were included in the study. Each participant underwent two fMRIs while performing the Wisconsin Card Sorting Task 20 months apart. The non-MCI patients recruited the usual cognitive corticostriatal loop at the first and second sessions (Time 1 and Time 2, respectively). However, decreased activity was observed in the cerebellum and occipital area and increased activity was observed in the medial prefrontal cortex and parietal lobe during planning set-shift at Time 2. Increased activity in the precuneus was also demonstrated while executing set-shifts at Time 2. The MCI patients revealed more activity in the frontal, parietal and occipital lobes during planning set-shifts, and in the parietal and occipital lobes, precuneus, and cerebellum, during executing set-shift at Time 2. Analysis regrouping of both groups of PD patients revealed that hippocampal and thalamic activity at Time 1 was associated with less cognitive decline over time. Our results reveal that functional alteration along the time-points differed between the non-MCI and MCI patients. They also underline the importance of preserving thalamic and hippocampal function with respect to cognitive decline over time.
Collapse
Affiliation(s)
- Atsuko Nagano-Saito
- Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal Montréal, QC, Canada
| | - Mohamed S Al-Azzawi
- Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal Montréal, QC, Canada
| | - Alexandru Hanganu
- Departments of Clinical Neurosciences and Radiology, University of CalgaryCalgary, AB, Canada; Hotchkiss Brain InstituteCalgary, AB, Canada
| | - Clotilde Degroot
- Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal Montréal, QC, Canada
| | - Béatriz Mejia-Constain
- Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal Montréal, QC, Canada
| | - Christophe Bedetti
- Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal Montréal, QC, Canada
| | | | - Valérie Soland
- Centre Hospitalier de l'Université de Montréal Montréal, QC, Canada
| | | | - Oury Monchi
- Centre de Recherche de l'Institut Universitaire de Gériatrie de MontréalMontréal, QC, Canada; Departments of Clinical Neurosciences and Radiology, University of CalgaryCalgary, AB, Canada; Hotchkiss Brain InstituteCalgary, AB, Canada; Department of Neurology and Neurosurgery, McGill UniversityMontreal, QC, Canada
| |
Collapse
|
12
|
Habak C, Noreau A, Nagano-Saito A, Mejía-Constaín B, Degroot C, Strafella AP, Chouinard S, Lafontaine AL, Rouleau GA, Monchi O. Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease. Brain 2014; 137:3025-35. [PMID: 25212851 PMCID: PMC4208466 DOI: 10.1093/brain/awu251] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2014] [Revised: 07/09/2014] [Accepted: 07/23/2014] [Indexed: 01/27/2023] Open
Abstract
Parkinson's disease is a neurodegenerative condition that affects motor function along with a wide range of cognitive domains, including executive function. The hallmark of the pathology is its significant loss of nigrostriatal dopamine, which is necessary for the cortico-striatal interactions that underlie executive control. Striatal dopamine reuptake is mediated by the SLC6A3 gene (formerly named DAT1) and its polymorphisms, which have been largely overlooked in Parkinson's disease. Thirty patients (ages 53-68 years; 19 males, 11 females) at early stages of Parkinson's disease, were genotyped according to a 9-repeat (9R) or 10-repeat (10R) allele on the SLC6A3/DAT1 gene. They underwent neuropsychological assessment and functional magnetic resonance imaging while performing a set-shifting task (a computerized Wisconsin Card Sorting Task) that relies on fronto-striatal interactions. Patients homozygous on the 10R allele performed significantly better on working memory tasks than 9R-carrier patients. Most importantly, patients carrying a 9R allele exhibited less activation than their 10R homozygous counterparts in the prefrontal cortex, premotor cortex and caudate nucleus, when planning and executing a set-shift. This pattern was exacerbated for conditions that usually recruit the striatum compared to those that do not. This is the first study indicating that the SLC6A3/DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions that engage the striatum. Longitudinal studies are warranted to assess this polymorphism's effect on the clinical evolution of patients with Parkinson's disease, especially with cognitive decline.
Collapse
Affiliation(s)
- Claudine Habak
- 1 Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal, Montréal, Québec, H3W 1W5, Canada
| | - Anne Noreau
- 2 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Québec, Canada 3 Department of Neurology and Neurosurgery, McGill University, Montréal, QC H3A 2B4, Canada
| | - Atsuko Nagano-Saito
- 1 Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal, Montréal, Québec, H3W 1W5, Canada
| | - Beatriz Mejía-Constaín
- 1 Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal, Montréal, Québec, H3W 1W5, Canada
| | - Clotilde Degroot
- 1 Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal, Montréal, Québec, H3W 1W5, Canada
| | - Antonio P Strafella
- 4 Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada
| | - Sylvain Chouinard
- 2 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Québec, Canada
| | - Anne-Louise Lafontaine
- 3 Department of Neurology and Neurosurgery, McGill University, Montréal, QC H3A 2B4, Canada
| | - Guy A Rouleau
- 2 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Québec, Canada 3 Department of Neurology and Neurosurgery, McGill University, Montréal, QC H3A 2B4, Canada
| | - Oury Monchi
- 1 Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal, Montréal, Québec, H3W 1W5, Canada 5 Département de Radiologie, Université de Montréal, Montréal, Québec, Canada
| |
Collapse
|
13
|
Hanganu A, Degroot C, Monchi O, Bedetti C, Mejia-Constain B, Lafontaine AL, Chouinard S, Bruneau MA. Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease. Front Neurol 2014; 5:188. [PMID: 25309508 PMCID: PMC4174860 DOI: 10.3389/fneur.2014.00188] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 09/10/2014] [Indexed: 01/04/2023] Open
Abstract
Introduction: Depressive symptoms are very common in patients with Parkinson’s disease (PD) and have a significant impact on the quality of life. Dopaminergic medication has been shown to have an influence on the development of depressive symptoms. Materials and methods: The present study analyzed two groups of non-demented patients with PD, with and without depressive symptoms, and reported the correlations between antiparkinsonian medication [specifically levodopa (l-DOPA) and dopaminergic agonists] with depressive symptoms. Results: A strong statistically significant positive correlation between l-DOPA dosages and the level of depressive symptoms has been revealed, suggesting that higher l-DOPA dosages correlate with a worsening of depressive status. No significant correlation was found with dopamine agonists. Discussion: The results of this study show that in patients with PD, higher l-DOPA dosages correlate with worse depressive symptoms. From this point of view, PD patients need to be better diagnosed with respect to depressive symptoms and need additional treatment adjustment when clinical manifestations of depression are present. Clinicians must be aware that dopaminergic drugs are not sufficient to alleviate depressive symptoms.
Collapse
Affiliation(s)
- Alexandru Hanganu
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal , Montreal, QC , Canada
| | - Clotilde Degroot
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal , Montreal, QC , Canada
| | - Oury Monchi
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal , Montreal, QC , Canada ; Department of Radiology, Faculty of Medicine, University of Montreal , Montreal, QC , Canada
| | - Christophe Bedetti
- Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré Coeur de Montréal , Montreal, QC , Canada
| | - Béatriz Mejia-Constain
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal , Montreal, QC , Canada
| | - Anne-Louise Lafontaine
- Movement Disorders Unit, McGill University Health Center , Montreal, QC , Canada ; Department of Neurology, Montreal Neurological Hospital , Montreal, QC , Canada
| | - Sylvain Chouinard
- Unité des troubles du mouvement André Barbeau, Centre Hospitalier de l'Université de Montréal , Montreal, QC , Canada
| | - Marie-Andrée Bruneau
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal , Montreal, QC , Canada
| |
Collapse
|
14
|
Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, Chouinard S, Bruneau MA, Mellah S, Belleville S, Monchi O. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain 2014; 137:1120-9. [DOI: 10.1093/brain/awu036] [Citation(s) in RCA: 136] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
15
|
Hanganu A, Bedetti C, Jubault T, Gagnon JF, Mejia-Constain B, Degroot C, Lafontaine AL, Chouinard S, Monchi O. Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Mov Disord 2013; 28:1360-9. [PMID: 23801590 DOI: 10.1002/mds.25541] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Revised: 04/18/2013] [Accepted: 04/29/2013] [Indexed: 12/19/2022] Open
Abstract
Mild cognitive impairment (MCI) can occur early in the course of Parkinson's disease (PD), and its presence increases the risk of developing dementia. Determining the cortical changes associated with MCI in PD, thus, may be useful in predicting the future development of dementia. To address this objective, 37 patients with PD, divided into 2 groups according to the presence or absence MCI (18 with and 19 without) and 16 matched controls, underwent anatomic magnetic resonance imaging. Corticometry analyses were performed to measure the changes in cortical thickness and surface area as well as their correlation with disease duration. Compared with healthy controls, the PD-MCI group exhibited increased atrophy and changes of local surface area in the bilateral occipital, left temporal, and frontal cortices; whereas the PD non-MCI group exhibited only unilateral thinning and decreased surface area in the occipital lobe and in the frontal cortex. In addition, a comparison between the PD-MCI and PD non-MCI groups revealed increased local surface area in the occipital lobe, temporal lobe, and postcentral gyrus for the cognitively impaired patients. It is noteworthy that, in the PD-MCI group, cortical thickness had a significant negative correlation with disease duration in the precentral, supramarginal, occipital, and superior temporal cortices; whereas, in the PD non-MCI group, such a correlation was absent. The findings from this study reveal that, at the same stage of PD evolution, the presence of MCI is associated with a higher level of cortical changes, suggesting that cortical degeneration is increased in patients with PD because of the presence of MCI.
Collapse
Affiliation(s)
- Alexandru Hanganu
- Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
It is now clear that cognitive deficits exist even early in Parkinson's disease, having a significant impact on daily activities. However, the nature and the neural origins of cognitive dysfunction in PD are still under debate. Furthermore, a great heterogeneity seems to exist with respect to the cognitive profiles found in patients at the early stages of the disease, and these initial differences are likely predictive of distinct outcomes regarding the later occurrence of dementia. These include the early presence of Mild Cognitive Impairments, the nature and number of domains affected, as well as the occurrence of depression or apathy. Here, we will review studies involving anatomical and functional neuroimaging, and neuropsychological evaluation that have attempted to address these issues. Recommendations for future work will also be discussed.
Collapse
Affiliation(s)
- Oury Monchi
- Research Centre, Institut Universitaire de Gériatrie de Montréal, QC, Canada.
| | | | | | | |
Collapse
|
17
|
Martinu K, Degroot C, Madjar C, Strafella AP, Monchi O. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease. Eur J Neurosci 2012; 35:572-83. [PMID: 22304628 DOI: 10.1111/j.1460-9568.2011.07979.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Motor studies of Parkinson's disease (PD) have shown cortical hypo-activity in relation to nigrostriatal dopamine depletion. Cognitive studies also identified increased cortical activity in PD. We have previously suggested that the hypo-activity/hyper-activity patterns observed in PD are related to the striatal contribution. Tasks that recruit the striatum in control participants are associated with cortical hypo-activity in patients with PD, whereas tasks that do not result in cortical hyper-activity. The putamen, a structure affected by the neurodegeneration observed in PD, shows increased activation for externally-triggered (ET) and self-initiated (SI) movements. The first goal of this study was to evaluate the effect of levodopa on the putamen's response to ET and SI movements. Our second goal was to assess the effect of levodopa on the hypo-activity/hyper-activity patterns in cortical areas. Patients with PD on and off levodopa and healthy volunteers performed SI, ET and control finger movements during functional magnetic resonance imaging. Healthy participants displayed significant differences in putamen activity in ET and SI movements. These differences were reduced in patients off medication, with non-task-specific increases in activity after levodopa administration. Furthermore, the ventrolateral prefrontal cortex showed significant increases in activity during SI movements in healthy controls, whereas it was hypo-active in PD. This region showed significantly increased activity during ET movements in patients off medication. Levodopa had no effect on this discrepancy. Our results suggest that dopamine replacement therapy has a non-task-specific effect on motor corticostriatal regions, and support the hypothesis that increases and decreases in cortical activity in PD are related to the mesocortical dopamine pathway imbalance.
Collapse
Affiliation(s)
- K Martinu
- Functional Neuroimaging Unit, Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, 4545 Queen Mary, Montréal, QC, H3W 1W5, Canada
| | | | | | | | | |
Collapse
|
18
|
Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, Lafontaine AL, Chouinard S, Monchi O. Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PLoS One 2009; 4:e8247. [PMID: 20011063 PMCID: PMC2784293 DOI: 10.1371/journal.pone.0008247] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2009] [Accepted: 11/12/2009] [Indexed: 11/18/2022] Open
Abstract
Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder characterized by the dysfunction of dopaminergic dependent cortico-basal ganglia loops and diagnosed on the basis of motor symptoms (tremors and/or rigidity and bradykinesia). Post-mortem studies tend to show that the destruction of dopaminergic neurons in the substantia nigra constitutes an intermediate step in a broader neurodegenerative process rather than a unique feature of Parkinson's disease, as a consistent pattern of progression would exist, originating from the medulla oblongata/pontine tegmentum. To date, neuroimaging techniques have been unable to characterize the pre-symptomatic stages of PD. However, if such a regular neurodegenerative pattern were to exist, consistent damages would be found in the brain stem, even at early stages of the disease. We recruited 23 PD patients at Hoenn and Yahr stages I to II of the disease and 18 healthy controls (HC) matched for age. T1-weighted anatomical scans were acquired (MPRAGE, 1 mm3 resolution) and analyzed using an optimized VBM protocol to detect white and grey matter volume reduction without spatial a priori. When the HC group was compared to the PD group, a single cluster exhibited statistical difference (p<0.05 corrected for false detection rate, 4287 mm3) in the brain stem, between the pons and the medulla oblongata. The present study provides in-vivo evidence that brain stem damage may be the first identifiable stage of PD neuropathology, and that the identification of this consistent damage along with other factors could help with earlier diagnosis in the future. This damage could also explain some non-motor symptoms in PD that often precede diagnosis, such as autonomic dysfunction and sleep disorders.
Collapse
Affiliation(s)
- Thomas Jubault
- Unité de Neuroimagerie Fonctionelle, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
|